ES2540057T3 - Composiciones líquidas que comprenden fenilefrina y acetaminofeno y su uso en el tratamiento de enfermedades respiratorias - Google Patents

Composiciones líquidas que comprenden fenilefrina y acetaminofeno y su uso en el tratamiento de enfermedades respiratorias Download PDF

Info

Publication number
ES2540057T3
ES2540057T3 ES07735699.6T ES07735699T ES2540057T3 ES 2540057 T3 ES2540057 T3 ES 2540057T3 ES 07735699 T ES07735699 T ES 07735699T ES 2540057 T3 ES2540057 T3 ES 2540057T3
Authority
ES
Spain
Prior art keywords
acetaminophen
phenylephrine
treatment
liquid compositions
respiratory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07735699.6T
Other languages
English (en)
Other versions
ES2540057T5 (es
Inventor
Kelly Lee Martin
Susan Elaine Criss
Douglas William Gledhill
Aloysius Ike Ononye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38480519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2540057(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of ES2540057T3 publication Critical patent/ES2540057T3/es
Application granted granted Critical
Publication of ES2540057T5 publication Critical patent/ES2540057T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición líquida que comprende una sustancia farmacéuticamente activa seleccionada de fenilefrina, sus formas libre y de sal de adición, y mezclas de las mismas; y acetaminofeno, estando caracterizada la composición por un pH de 6,75 a 7,5.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
E07735699
22-06-2015
Ejemplo 1
Se ilustran a continuación varios ejemplos de composiciones de la presente invención. Todos los ejemplos siguientes tendrán un pH de aproximadamente 7,1.
Descripción del material
% p/p % p/p % p/p % p/p % p/p
Premezcla de glicol
Propilenglicol USP
16 16 12 8 16
Polietilenglicol 400 NF
0 4 8 8 8
Sorbitol
8 4 4 8 0
Acetaminofeno USP
1,78 1,78 1,78 1,78 1,78
Dextrometorfano HBr USP
0,05 0,05 0,05 0,05 0,05
Sabor
0,30 0,30 0,30 0,30 0,31
Premezcla de agua
Agua purificada USP
6,6 4 8 8 6,6
Citrato sódico hidratado USP
1,6 1,6 1,6 1,6 1,6
Fenilefrina
0,033 0,033 0,033 0,033 0,033
Ácido cítrico anhidro USP
0,02 0,02 0,02 0,02 0,02
Sacarina sódica USP
0,08 0,08 0,08 0,08 0,08
Color
0,06 0,06 0,06 0,06 0,06
Glicerina USP
4 8 16 12 4,1
Azúcar líquido n.°1
53,8 49 40 45 53,8
Agua purificada USP
c.s. c.s. c.s. c.s. c.s.
Propilenglicol comercializado por Dow Chemical Corp. Plaqremine, LA, EE. UU. Dextrometorfano HBr comercializado por Hoffman-LaRoche, Branchburg, NJ, EE. UU. Acetaminofeno comercializado por Mallinckrodt, Raleigh, NC, EE. UU.
10 Glicerina comercializada por Procter & Gamble Company, Cincinnati, OH, EE. UU. Citrato sódico comercializado por Hoffman-LaRoche, Branchburg, NJ, EE. UU. Ácido cítrico comercializado por ADM, Cork, Ireland Fenilefrina HCL comercializada por Iwaki, Ku Tokyo, Japan Sacarina sódica comercializada por PMC Specialties grupo, Inc., Cincinnati, OH, EE. UU.
15 Azúcar líquido comercializado por Imperial Sugar, Port Wentworth, CA, EE. UU.
8

Claims (1)

  1. imagen1
ES07735699.6T 2006-04-28 2007-04-27 Composiciones líquidas que comprenden fenilefrina y acetaminofeno y su uso en el tratamiento de enfermedades respiratorias Active ES2540057T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US413766 2003-04-15
US11/413,766 US20070254027A1 (en) 2006-04-28 2006-04-28 Compositions and methods useful for treatment of respiratory illness
PCT/IB2007/051583 WO2007125501A2 (en) 2006-04-28 2007-04-27 Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness

Publications (2)

Publication Number Publication Date
ES2540057T3 true ES2540057T3 (es) 2015-07-08
ES2540057T5 ES2540057T5 (es) 2018-07-03

Family

ID=38480519

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07735699.6T Active ES2540057T5 (es) 2006-04-28 2007-04-27 Composiciones líquidas que comprenden fenilefrina y acetaminofeno y su uso en el tratamiento de enfermedades respiratorias

Country Status (11)

Country Link
US (1) US20070254027A1 (es)
EP (1) EP2012765B2 (es)
JP (1) JP2009534372A (es)
CN (1) CN101431991B (es)
AU (1) AU2007245300B2 (es)
BR (1) BRPI0711065A2 (es)
CA (1) CA2649997C (es)
ES (1) ES2540057T5 (es)
MX (1) MX2008013664A (es)
PL (1) PL2012765T5 (es)
WO (1) WO2007125501A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TR201107202T1 (tr) * 2008-11-11 2012-02-21 Berko İlaç Ve Ki̇mya Sanayi̇ A.Ş. İbuprofen, psödoefedrin ve klorfeniramin içeren bir farmasötik bileşim.
US8518439B2 (en) * 2008-12-03 2013-08-27 Novartis Ag Liquid therapeutic composition
US20130101578A1 (en) * 2010-04-12 2013-04-25 National University Of Singapore Biomarker for renal function in patients with type 2 diabetes
MX2015009681A (es) * 2013-02-04 2016-07-11 Aft Pharmaceuticals Ltd Un medicamento combinado que comprende finilefrina y paracetamol.
US20140221494A1 (en) * 2013-02-04 2014-08-07 Aft Pharmaceuticals Ltd. Medicament
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
CN104122360B (zh) * 2014-08-04 2016-05-25 人福普克药业（武汉）有限公司 利用高效液相色谱分析氨美敏ⅱ软胶囊的方法
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
ES2863988T3 (es) 2015-05-21 2021-10-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Formulaciones farmacéuticas con mejor solubilidad y estabilidad
US20180263916A1 (en) * 2015-09-28 2018-09-20 Puracap Pharmaceutical Llc Soft gelatin capsules containing a mixture of analgesics and decongestants, expectorants, antitussives and/or antihistamines
CN107569504B (zh) * 2016-07-04 2020-06-09 珠海同源药业有限公司 一种盐酸氨溴索分散片及制备方法
EP3506885A1 (en) * 2016-09-01 2019-07-10 The Procter and Gamble Company Medication with improved taste and sensory experience
CA3100314A1 (en) 2018-05-16 2019-11-21 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN109044968B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚右美肾素口服液及其制备方法
CN109045003B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚拉明肾素口服液及其制备方法
CN109125257B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚愈创肾素口服液及其制备方法
CN110279695B (zh) * 2019-08-07 2022-04-08 北京博智绿洲医药科技有限公司 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
WO2024086268A1 (en) * 2022-10-19 2024-04-25 Fresenius Kabi Austria Gmbh Phenylephrine liquid formulations
CN115998739A (zh) * 2022-12-27 2023-04-25 广州艾格生物科技有限公司 一种治疗感冒症状的复方制剂及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480185A (en) * 1966-06-20 1969-11-25 Johnson & Johnson Charged effervescing agent and medicament dispensing metering valve-actuated aerosol container producing a dose of medicament and carbonation in water
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5480674A (en) * 1993-06-25 1996-01-02 Firmenich Incorporated Flavor composition for an oral electrolyte rehydration solution
GB9422571D0 (en) 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
JPH09286726A (ja) * 1996-04-18 1997-11-04 Takeda Chem Ind Ltd 経口液剤
JPH09286724A (ja) * 1996-04-19 1997-11-04 Takeda Chem Ind Ltd 経口用安定液剤
JPH09286723A (ja) * 1996-04-19 1997-11-04 Takeda Chem Ind Ltd 改善された経口液剤
JPH10167988A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd 経口液剤
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
KR100776577B1 (ko) * 2000-05-17 2007-11-16 센주 세이야꾸 가부시키가이샤 점안제
JP2002212107A (ja) * 2001-01-22 2002-07-31 Taisho Pharmaceut Co Ltd 局所適用組成物
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
JPWO2004037293A1 (ja) * 2002-10-22 2006-02-23 大日本住友製薬株式会社 安定化組成物
JP2004217596A (ja) * 2003-01-17 2004-08-05 Taisho Pharmaceut Co Ltd 点眼剤組成物
US20040162273A1 (en) * 2003-01-23 2004-08-19 The Procter & Gamble Company Powder pharmaceutical compositions
JP2004300138A (ja) * 2003-03-18 2004-10-28 Takeda Chem Ind Ltd 安定化された経口固形製剤
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness

Also Published As

Publication number Publication date
AU2007245300A1 (en) 2007-11-08
PL2012765T5 (pl) 2018-09-28
BRPI0711065A2 (pt) 2011-08-23
EP2012765B2 (en) 2018-04-11
ES2540057T5 (es) 2018-07-03
CN101431991A (zh) 2009-05-13
WO2007125501A2 (en) 2007-11-08
AU2007245300B2 (en) 2012-06-07
WO2007125501A3 (en) 2008-01-10
CN101431991B (zh) 2012-04-04
US20070254027A1 (en) 2007-11-01
CA2649997A1 (en) 2007-11-08
MX2008013664A (es) 2008-11-04
EP2012765A2 (en) 2009-01-14
JP2009534372A (ja) 2009-09-24
EP2012765B1 (en) 2015-03-25
CA2649997C (en) 2012-11-20
PL2012765T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
ES2540057T3 (es) Composiciones líquidas que comprenden fenilefrina y acetaminofeno y su uso en el tratamiento de enfermedades respiratorias
ES2667331T3 (es) Composiciones de fenilefrina útiles para el tratamiento de enfermedades respiratorias
ES2625944T3 (es) Inhibidores de tirosina cinasa de Bruton
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
AR031450A1 (es) Composiciones orales que tienen caracteristicas esteticas del consumidor mejoradas
EA201270069A1 (ru) Быстрорастворимая оральная пленочная лекарственная форма, содержащая стевиозиды в качестве агента, маскирующего неприятный вкус
ES2567130T3 (es) Uso de compuestos de éster del ácido hidroxibenzoico para la fabricación de un medicamento para la prevención y tratamiento de infección por VPH
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
HUP0204159A2 (hu) Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására
KR101506382B1 (ko) 구강세척용 발포 조성물
ES2644373T3 (es) Comprimido efervescente que contiene elevado nivel de aspirina
ES2212550T3 (es) Solucion oral liquida que comprende el antidepresor mirtazapina.
MX2022008191A (es) Soluciones orales que comprenden sales de lisdexanfetamina.
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
ES2312921T3 (es) Disolucion acuosa concentrada de ambroxol.
ES2318277T3 (es) Composicion farmaceutica que compresnde acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico.
UA79110C2 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
ES2199461T3 (es) Antagonista de endotelina y bloqueador de los beta receptores a modo de preparado en combinacion.
PE20010568A1 (es) Formulaciones orales de liberacion controlada
ES2507570T3 (es) Terapia de combinación de Zn/trimetoprim
AR033331A1 (es) Formas polimorfas de un citrato de azabiciclo [2,2,2] octan-3-amina, sus composiciones farmaceuticas, procedimiento de tratamiento y procedimiento para su produccion.
HUP0204111A2 (hu) Új eljárás alfa-(2,4-diszulfo-fenil)-N-terc-butil-nitron és gyógyszerészetileg elfogadható sói előállítására
PE20020055A1 (es) Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal
RU2007132264A (ru) Пролекарственные формы 1r, 2s-метоксамина, способ получения таких пролекарственных форм (варианты), фармацевтическая композиция, включающая их, и способ лечения недержания мочи посредством таких пролекарственных форм
AU2016219620B2 (en) Compositions and methods useful for treatment of respiratory illness